Inlybest-1

Mild or major side effects may occur during treatment with Inlybest 1mg tablets. If side effects last longer than usual, inform your general practitioner as soon as possible.

• ​Stomach pain
  
• Heartburn 
  
• Headache 
  
• Dizziness 
  
• Rash 
  
• Itching 
  
• Dry skin
  
• Pale skin
  
• Fast heartbeat
  
• Hair loss
  
• Ringing in the ears
  
• Thirst 
  
• Hemorrhoids 
  
• A wound or cut that will not heal
  
• Diarrhea 

​Take the Inlybest 1mg tablet as prescribed by your health professional. Ensure you take this cancer-fighting formulation in the same amount as directed by your physician. In case of an overdose, the patient is advised to consult a general practitioner as soon as possible if any unusual symptoms occur.

Inlybest 1mg tablet should be swallowed as a whole. Let your doctor know if you have liver, thyroid, kidney disease, etc, or are on some other medications. Inlybest tablet is not recommended for pregnant and breastfeeding women.

Inlybest 1mg tablet helps prevent the progression of cancer by inhibiting angiogenesis and blocking tumor growth. It selectively blocks the tyrosine kinase receptors VEGFR-1 (vascular endothelial growth factor receptor), VEGFR-2, and VEGFR-3.

The formulation is mainly eliminated in the feces (about 41%) with nearly 12% of the original dose as unchanged axitinib. There is also 23% eliminated in the urine, most of which are metabolites.

​If you miss a scheduled dose of Inlybest-1 tablet, contact your medical practitioner immediately to know the ways of coping with the missed or skipped dose.​

1. Gross-Goupil M, François L, Quivy A, Ravaud A. (2023). Axitinib: a review of its safety and efficacy in the treatment of adults with advanced renal cell carcinoma. Clin Med Insights Oncol. 29(7):269-77 - https://pubmed.ncbi.nlm.nih.gov/24250243/
2. Keating GM. (2023). Axitinib: a review in advanced renal cell carcinoma. Drugs. 75(16):1903-13 - https://pubmed.ncbi.nlm.nih.gov/26487541/
3. Mi-Hyang Jung, Yun-Seok Choi, Sang-Wook Yi, Sang Joon An, Jee-Jeon Yi, Sang-Hyun Ihm, So-Young Lee, Jong-Chan Youn, Woo-Baek Chung, Hae Ok Jung, Ho-Joong Youn. (2025). Socioeconomic status and cardiovascular mortality in over 170,000 cancer survivors, European Heart Journal - Quality of Care and Clinical Outcomes, 11(4), 406–414 - https://pubmed.ncbi.nlm.nih.gov/38964851/
4. Oldani M, Cantone MC, Gaudenzi G, Carra S, Dicitore A, Saronni D, Borghi MO, Lombardi A, Caraglia M, Persani L, Vitale G. (2024). Exploring the multifaceted antitumor activity of axitinib in lung carcinoids. Front Endocrinol (Lausanne) - https://pubmed.ncbi.nlm.nih.gov/39050569/
5. Shin SJ, Lee JL, Kwon TG, Shim BY, Chung HS, Kim SH, Park SH.(2025). Real-World Study Evaluating Safety and Effectiveness of Axitinib in Korean Patients with Renal Cell Carcinoma after Failure of One Prior Systemic Therapy. Cancer Res Treat. 55(2):643-651 - https://pubmed.ncbi.nlm.nih.gov/36470258/
6. Tzogani K, Skibeli V, Westgaard I, Dalhus M, Thoresen H, Slot KB, Damkier P, Hofland K, Borregaard J, Ersbøll J, Salmonson T, Pieters R, Sylvester R, Mickisch G, Bergh J, Pignatti F. (2024). The European Medicines Agency approval of axitinib (Inlyta) for the treatment of advanced renal cell carcinoma after failure of prior treatment with sunitinib or a cytokine: summary of the scientific assessment of the committee for medicinal products for human use. Oncologist. ;20(2):196-201.